Soru

To evaluate the efficacy of a novel immunomodulator in preventing clinical relapses among patients with relapsing-remitting multiple sclerosis, researchers conduct a phase III, placebo-controlled, double-blind trial. A total of $2,000$ enrolled patients are randomized in a 1:1 ratio to receive either the novel immunomodulator or a placebo. After two years of continuous follow-up, $140$ patients in the placebo arm and $95$ patients in the intervention arm experienced at least one clinical relapse. In their primary analysis, the investigators report the absolute risk reduction alongside a 95% confidence interval of $0.021$ to $0.069$.

Determine the number of patients that must be treated with the novel immunomodulator to prevent one additional clinical relapse, and appropriately characterize the statistical significance based on the reported absolute risk reduction confidence interval.